Minimal Residual Disease Testing Market: Trends, Growth Drivers, and Key Players
According to a recent report, the global minimal residual disease testing market is poised for remarkable growth, projected to reach USD 2.3 billion by 2027, with a robust compound annual growth rate of 14.0%. This surge is fueled by various factors including the increasing prevalence of cancer and hematological malignancies, proactive initiatives by government bodies to raise awareness about cancer, and the burgeoning collaborations within the healthcare sector. Emerging economies such as China, Japan, and India are offering lucrative opportunities for stakeholders in this market, further amplifying its growth trajectory. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=215386038 The polymerase chain reaction (PCR) segment emerges as a frontrunner within the minimal residual disease testing market, accounting for the largest share in 2021. This dominance is attributed to the technology's simplicity, availability, relative sensitivity, an...